公开(公告)号：KR101613835B1

公开(公告)日：2016-04-21

申请号：KR1020140077026

申请日：2014-06-24

Applicant: 전남대학교산학협력단

Inventor： 강형식 ,  윤철호 ,  장지훈 ,  이화연 ,  오승수

IPC: A61K36/605

Abstract: 본발명은시토크롬 P450 효소로전환된오디추출물을포함하는염증성장질환의예방또는치료용약학조성물에관한것으로, 상세하게는시토크롬 P450 효소로전환된오디추출물로염증성장질환을완화시키고, 비정상적으로과도화된활성면역세포를조절하는약학조성물에관한것이다. 본발명을통해, P450 효소전환된오디추출물이대장조직내에점막의면역조절활성을유도함으로써, 염증성장질환의개선, 예방또는치료에유용하게활용될수 있을것으로기대된다.

公开(公告)号：KR1020150010326A

公开(公告)日：2015-01-28

申请号：KR1020130085180

申请日：2013-07-19

Applicant: 전남대학교산학협력단

Inventor： 강형식 ,  박민 ,  윤일주 ,  정윤화 ,  김상희 ,  강건욱 ,  임채민

IPC: A61K31/34 ,  A61K31/166 ,  A61K31/16 ,  A61P3/04

Abstract: The present invention relates to a composition for preventing or treating obesity and type 2 diabetes, or hepatic steatosis and, more specifically, to a composition for preventing or treating obesity and type 2 diabetes, or hepatic steatosis, containing derivatives including a main adipose differentiation promotion factor inhibitor or biaryl amide as an active ingredient. Additionally, by inhibiting a main adipose differentiation promotion factor and increasing Wnt10b, the composition according to the present invention can control differentiation of adipocytes, and increase insulin resistance and glucose resistance, thereby being effectively used for treating obesity and type 2 diabetes, or hepatic steatosis.

Abstract translation: 本发明涉及用于预防或治疗肥胖症和2型糖尿病或肝脂肪变性的组合物，更具体地，涉及用于预防或治疗肥胖症和2型糖尿病或肝脂肪变性的组合物，其包含主要脂肪分化促进的衍生物 因子抑制剂或联芳基酰胺作为活性成分。 另外，通过抑制主要的脂肪分化促进因子和增加Wnt10b，本发明的组合物可以控制脂肪细胞的分化，增加胰岛素抵抗和葡萄糖耐量，从而有效地用于治疗肥胖和2型糖尿病或肝脂肪变性 。

公开(公告)号：KR1020130101493A

公开(公告)日：2013-09-13

申请号：KR1020130102400

申请日：2013-08-28

Applicant: 전남대학교산학협력단

Inventor： 강형식 ,  윤철호 ,  박민 ,  윤일주

IPC: A61K31/05 ,  A61K31/09 ,  A61P3/04 ,  A61P3/10

Abstract: PURPOSE: A use of resverastrol derivatives is provided to suppress triggering receptor expressed on myeloid cells-2 (TREM-2) and to regulate the expression of genes related to insulin metabolism and adipocyte differentiation, thereby effectively treating obesity or type 2 diabetes. CONSTITUTION: A method for suppressing TREM-2 in animals exclusive of human comprises the step of administering a composition containing one or more selected among piceatannol, piceid, and pterostilbene as active ingredients to an individual. A method for treating obesity or type 2 diabetes caused by overexpression of TREM-2 gene in animals exclusive of human comprises the step of administering the composition to an individual. A method for increasing the expression of leptin, TNFalpha gene, and adiponectin gene in a TREM-2 transgenic mouse comprises the step of administering the composition to an individual.

Abstract translation: 目的：提供使用白藜芦醇衍生物以抑制在骨髓细胞-2（TREM-2）上表达的触发受体并调节与胰岛素代谢和脂肪细胞分化相关的基因的表达，从而有效治疗肥胖或2型糖尿病。 构成：不包括人类的动物中抑制TREM-2的方法包括向个体施用含有作为活性成分的作为活性成分的作为活性成分的皮质烷醇，皮质和蝶啶中的一种或多种的组合物的步骤。 在不包括人类的动物中，TREM-2基因过表达引起的肥胖症或2型糖尿病的治疗方法包括向个体施用组合物的步骤。 在TREM-2转基因小鼠中增加瘦素，TNFα基因和脂连蛋白基因表达的方法包括向个体施用组合物的步骤。

公开(公告)号：KR1020110035554A

公开(公告)日：2011-04-06

申请号：KR1020090093323

申请日：2009-09-30

Applicant: 전남대학교산학협력단

Inventor： 지연태 ,  강형식 ,  마상훈 ,  최고우

IPC: C12N1/00 ,  A61P35/00 ,  A61P37/04 ,  C12R1/07

Abstract: PURPOSE: A mixture strain of Bacillus sp. CMB L1 and Lactobacillus sp. CMB201 is provided to be used as a microbial formulation. CONSTITUTION: A Bacillus sp. CMB L1(KCTC 18135) and Lactobacillus sp. CMB 201(KCTC 18136) are isolated from soybean paste and have thrombolysis activity and anticancer activity. A food composition for anticancer and immunity enhancement contains the Bacillus sp. CMB L1(KCTC 18135) and Lactobacillus sp. CMB 201(KCTC 18136) or culture thereof.

Abstract translation: 目的：芽孢杆菌属混合菌株 CMB L1和乳杆菌属 提供CMB201用作微生物制剂。 构成：芽孢杆菌 CMB L1（KCTC 18135）和Lactobacillus sp。 CMB 201（KCTC 18136）与大豆酱分离，具有溶栓活性和抗癌活性。 用于抗癌和免疫增强的食物组合物包含芽孢杆菌属（Bacillus sp。 CMB L1（KCTC 18135）和Lactobacillus sp。 CMB 201（KCTC 18136）或其培养物。

公开(公告)号：KR1020090090946A

公开(公告)日：2009-08-26

申请号：KR1020080016523

申请日：2008-02-22

Applicant: 전남대학교산학협력단

Inventor： 강형식 ,  김은미 ,  김동헌 ,  이은희 ,  최하림 ,  이화연

IPC: A61K39/395 ,  A61K38/00 ,  A61P35/00

CPC classification number: A61K39/39566 ,  A61K38/00 ,  Y10S514/885

Abstract: A composition for preventing and treating cervical cancer, which comprises lymphotoxin alpha/beta complex (LTalpha/beta) or lymphotoxin beta receptor (LTbeta-R) binding agent is provided to use an agent for preventing or treating cervical cancer by inducing the mucosa immune response. A composition for preventing and treating cervical cancer comprises limphotoxin alpha/beta complex or limphotoxin beta receptor binding agent as an active ingredient. The lymphotoxin alpha/beta complex is a surface lymphotoxin alpha/beta complex or recombinant soluble lymphotoxin alpha/beta complex. The lymphotoxin beta receptor is an antibody to lymphotoxin beta receptor. The antigen is polyclonal antibody or monoclonal antibody.

Abstract translation: 提供了一种用于预防和治疗宫颈癌的组合物，其包括淋巴毒素α/β复合物（LTα/β）或淋巴毒素β受体（LTbeta-R）结合剂，用于通过诱导粘膜免疫应答来预防或治疗宫颈癌 。 用于预防和治疗宫颈癌的组合物包含角光素α/β复合物或角叉松素β受体结合剂作为活性成分。 淋巴毒素α/β复合物是表面淋巴毒素α/β复合物或重组可溶性淋巴毒素α/β复合物。 淋巴毒素β受体是淋巴毒素β受体的抗体。 抗原是多克隆抗体或单克隆抗体。

公开(公告)号：KR100650384B1

公开(公告)日：2006-11-30

申请号：KR1020060070390

申请日：2006-07-26

Applicant: 전남대학교산학협력단 ,  주식회사 굿셀라이프

Inventor： 강형식 ,  김은미 ,  김상현 ,  윤지연 ,  고창보 ,  허영진 ,  심우영 ,  허성범 ,  이은희 ,  윤희정

IPC: C07K2/00

Abstract: A method for differentiating precursor natural killer cell into mature natural killer cell is provided to obtain large amount of the mature natural killer cell by treating the precursor natural killer cell with Axl receptor tyrosine kinase. The composition for inducing differentiation of precursor natural killer cell into mature natural killer cell is characterized in that it includes at least one ligand selected from the group consisting of antibody of Axl receptor tyrosine kinase(Axl), gamma-carboxylated growth-arrest specific gene6(Gas6) protein and protein S as a ligand of the Axl. The method comprises the steps of: (a) treating hematopoietic stem cell with interleukin-7, stem cell factor and Flt3 ligand to be differentiated into precursor natural killer cell; and (b) treating the precursor natural killer cell with at least one selected from the group consisting of antibody of Axl receptor tyrosine kinase(Axl), gamma-carboxylated growth-arrest specific gene6(Gas6) protein and protein S.

Abstract translation: 通过用Axl受体酪氨酸激酶处理前体天然杀伤细胞来提供将前体天然杀伤细胞分化为成熟天然杀伤细胞以获得大量成熟天然杀伤细胞的方法。 用于诱导前体天然杀伤细胞分化为成熟自然杀伤细胞的组合物的特征在于其包含至少一种选自Axl受体酪氨酸激酶抗体（Axl），γ-羧化生长抑制特异性基因6（ Gas6）蛋白和蛋白S作为Axl的配体。 该方法包括以下步骤：（a）用白细胞介素-7，干细胞因子和Flt3配体处理造血干细胞以分化成前体天然杀伤细胞; 和（b）用选自Axl受体酪氨酸激酶抗体（Axl），γ-羧化生长抑制特异性基因6（Gas6）蛋白质和蛋白质S中的至少一种处理前体天然杀伤细胞。

公开(公告)号：KR102226873B1

公开(公告)日：2021-03-11

申请号：KR1020190067241

申请日：2019-06-07

Applicant: 전남대학교산학협력단

Inventor： 윤철호 ,  카오응억딴 ,  강형식

IPC: C07D309/30 ,  C12P17/06

Abstract: 본발명의일 실시예는하기화학식 1로표시되는스타틴계화합물인 6'-하이드록시메틸-모나콜린 J(6'-hydroxymethyl-monacolin J) 및이의제조방법을제공한다: [화학식 1] JPEG112019058262388-pat00004.jpg4044

公开(公告)号：KR1020200140530A

公开(公告)日：2020-12-16

申请号：KR1020190067241

申请日：2019-06-07

Applicant: 전남대학교산학협력단

Inventor： 윤철호 ,  카오응억딴 ,  강형식

IPC: C07D309/30 ,  C12P17/06

Abstract: 본발명의일 실시예는하기화학식 1로표시되는스타틴계화합물인 6'-하이드록시메틸-모나콜린 J(6'-hydroxymethyl-monacolin J) 및이의제조방법을제공한다: [화학식 1] JPEGpat00004.jpg4044

公开(公告)号：KR101958346B1

公开(公告)日：2019-03-15

申请号：KR1020170136365

申请日：2017-10-20

Applicant: 전남대학교산학협력단

Inventor： 윤철호 ,  장현희 ,  레티엔킴 ,  강형식

IPC: C07D471/04 ,  A61K31/437

公开(公告)号：KR100967623B1

公开(公告)日：2010-07-05

申请号：KR1020080016523

申请日：2008-02-22

Applicant: 전남대학교산학협력단

Inventor： 강형식 ,  김은미 ,  김동헌 ,  이은희 ,  최하림 ,  이화연

IPC: A61K39/395 ,  A61K38/00 ,  A61P35/00

Abstract: 본 발명은 유효성분으로서 림포톡신 α/β 복합체(Lymphotoxin α/β Complex, LTα/β) 또는 림포톡신 β 수용체(Lymphotoxin β receptor, LTβ-R) 결합제를 포함하는, 자궁경부암 예방 또는 치료용 조성물에 관한 것으로서, 점막면역 반응을 효과적으로 유도함으로써 자궁경부암의 예방 또는 치료제로 유용하게 이용될 수 있다.
림포톡신, 림포톡신 α/β 복합체, LTα/β, 림포톡신 β 수용체, LTβ-R, 점막면역, 인유두종바이러스, HPV, E6, 자궁경부암